Sarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Oppenheimer Continues to Expect Sarepta (SRPT) Eteplirsen Approval in the Next Few Months
July 20, 2016 9:48 AM EDTOppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) following results. The analyst continues to expected FDA approval in the next few months.
Gilson commented, "Sarepta on July 19 reported 2Q16 financial results, ending the... More
